| Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer R Savla, O Taratula, O Garbuzenko, T Minko Journal of controlled release 153 (1), 16-22, 2011 | 398 | 2011 |
| Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery O Taratula, OB Garbuzenko, P Kirkpatrick, I Pandya, R Savla, ... Journal of Controlled Release 140 (3), 284-293, 2009 | 393 | 2009 |
| Review and analysis of FDA approved drugs using lipid-based formulations R Savla, J Browne, V Plassat, KM Wasan, EK Wasan Drug development and industrial pharmacy 43 (11), 1743-1758, 2017 | 229 | 2017 |
| Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells Y Xiao, X Gao, O Taratula, S Treado, A Urbas, RD Holbrook, RE Cavicchi, ... BMC cancer 9, 1-11, 2009 | 217 | 2009 |
| Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes T Minko Current Drug Delivery 8, 59-69, 2011 | 168 | 2011 |
| Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids V Shah, O Taratula, O B Garbuzenko, M L Patil, R Savla, M Zhang, ... Current drug discovery technologies 10 (1), 8-15, 2013 | 99 | 2013 |
| Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy R Savla, OB Garbuzenko, S Chen, L Rodriguez-Rodriguez, T Minko Pharmaceutical research 31, 3487-3502, 2014 | 51 | 2014 |
| Nanotechnology approaches for inhalation treatment of fibrosis R Savla, T Minko Journal of drug targeting 21 (10), 914-925, 2013 | 51 | 2013 |
| Nanoparticle design considerations for molecular imaging of apoptosis: Diagnostic, prognostic, and therapeutic value R Savla, T Minko Advanced drug delivery reviews 113, 122-140, 2017 | 39 | 2017 |
| Poly (propyleneimine) dendrimers as potential siRNA delivery nanocarrier: from structure to function O Taratula, R Savla, H He, T Minko International Journal of Nanotechnology 8 (1-2), 36-52, 2011 | 37 | 2011 |
| Nanoparticles in the development of therapeutic cancer vaccines R Savla, V Ivanova, T Minko Pharmaceutical Nanotechnology 2 (1), 2-22, 2014 | 8 | 2014 |
| Multifunctional siRNA delivery system for cancer therapy O Taratula, R Savla, I Pandya, H Geng, A Wang, T Minko, H He Une 13, 15, 2016 | 4 | 2016 |
| Oral delivery of macromolecular drugs R Savla, CM Lehr, B Loretz, O Hartwig, W Chin Pharmaceutical Technology 42 (7), 32–40-32–40, 2018 | 2 | 2018 |
| Novel superparamagnetic iron oxide nanoparticles for a multifunctional nanomedicine platform O Taratula, R Savla, I Pandya, A Wang, T Minko, H He MRS Fall Meeting 2008: Advances in Material Design for Regenerative Medicine …, 2009 | 2 | 2009 |
| The Truths and Myths of Oral Lipid-Based Dru g Delivery Systems W Ma, V Plassat, R Savla, K Li Am. Pharm. Rev 21, 32-35, 2018 | 1 | 2018 |
| Determination of Current Knowledge A Kuzmov, R Savla Solid State Development and Processing of Pharmaceutical Molecules: Salts …, 2021 | | 2021 |
| Preformulation and Physicochemical Characterization Underpinning the Development of Controlled Drug Delivery Systems R Savla, J Meissonnier Fundamentals of Drug Delivery, 73-94, 2021 | | 2021 |
| Bridging the Gap from Molecule to Drug S Tindal, R Savla Pharmaceutical Technology 42 (4), 72–77-72–77, 2018 | | 2018 |
| Analysis of Physicochemical Characteristics to Profile Drug Candidates Likely to Benefit from Lipid Formulation R Savla, J Browne, EK Wasan, K Wasan 2017 Controlled Release Society Annual Meeting, 2017 | | 2017 |
| Insights and Lessons from a Scientific Conference on Non-Invasive Delivery of Macromolecules R Savla, RJ Mrsny, K Park, I Aubert, C Stamoran Pharmaceutical Research 34, 1149-1151, 2017 | | 2017 |
